WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Vytrus Biotech
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Caris Life Sciences | March 09, 2023
Caris Life Sciences®, a leading molecular science and technology firm and Incyte Corporation have recently announced a strategic research partnership to advance precision medicine approaches for Incyte's oncology pipeline. Caris' innovative technology integrates data from whole exome sequencing, protein analysis, whole transcriptome sequencing and proprietary AI models and signatures to enhance patient outcomes through personalized medicine development. Th...
Connecticut Biotech | August 14, 2020
Connecticut Biotech, a new innovative start-up company, is announcing the launch of its Secure Fit 3D-printed face mask frame. The mask frames are an exoskeleton worn outside of a traditional surgical mask, providing enhanced efficacy in protection against COVID-19 and other airborne pathogens. Secure Fit is a reusable, reliable device designed to make day-to-day interactions safer for users.In partnership with the University of Connecticut and under the leadership of surgeon-scientist Dr....
Enlaza Therapeutics | December 19, 2022
Enlaza Therapeutics, the first covalent biologic platform company, announced its official launch with the closing of $61 million in seed financing. The financing was led by Avalon Ventures and joined by Lightspeed Venture Partners, Frazier Life Sciences, and Samsara BioCapital. The financing will be used to further advance Enlaza’s proprietary War-LockTM platform and build a pipeline of covalent biologics with an initial focus on developing novel, differentiated cancer therapeutics with ta...
MEDICAL
Genetic Leap | March 11, 2022
Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...
Video
Whitepaper
CELL AND GENE THERAPY
INDUSTRIAL IMPACT, MEDICAL
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE